Applications for the approval of Abiraterone Acetate (Abiraterone) have been submitted to both the U.S. Food and Drug Administration (FDA) and to the European Medicines Agency (EMA). The applications are for the approval of Abiraterone with prednisone for the treatment of metastatic advanced prostate cancer in men who have received prior chemotherapy containing a taxane. [...]
According to a study funded by Amgen Inc., the incidence of stage IV prostate cancer has significantly declined and survival has improved, but the scary side of the equation is that younger men represent an increasing proportion of those diagnosed. The study was published in the June issue of Urology. […]
Malecare has an on-line support group for men with advanced prostate cancer; their loved ones and caretakers. Today, there was a post on the support group where one of the participants shared their recent experience with Provenge, including some very specific recommendations for anyone else thinking of having the treatment. You can join us by [...]
According to the FDA approval label, zoledronic acid (Zometa) should be administered to men with advanced prostate cancer once they have failed one hormone therapy type, in other words, once the cancer has become castrate resistant. Researchers at the Centre Hospitalier de i’Université de Montréal, Hôpital Notre-Dame, Montréal, Quebec, Canada evaluated the effect of zoledronic [...]
Results from a recent clinical trial indicate that denosumab delayed the spread of prostate cancer metastases bones, however it did not prolong the lives of men. […]